홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

Ganirelix

HCID 16130957
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
124904-93-4
표준 SMILES
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC
InChIKey
GJNXBNATEDXMAK-PFLSVRRQSA-N
분자식
C80H113ClN18O13
평균 분자량
1,570.3 g/mol
단동위원소 질량
1,568.8423034

개요

Ganirelix is a polypeptide.

이름 및 식별자

우선 이름
Ganirelix
IUPAC
(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
영어명
GANIRELIX
분자식
C80H113ClN18O13
분자량
1570.32

이름 및 동의어

Ganirelix124904-93-4OrgalutranGanirelixumIX503L9WN0DTXSID401027283D-Alaninamide, N-acetyl-3-(1-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-(bis(ethylamino)methylene)-D-lysyl-L-leucyl-N6-(bis(ethylamino)methylene)-L-lysyl-L-prolyl-RefChem:58106H01CC01DTXCID401511553GnRH, N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)-LHRH,N-Ac-2-Nal(1)-4-Cl-Phe(2)-3-Pal(3)-Et2-hArg(6,8)-AlaNH2(10)-
이름 더 보기
RS 26306N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylamino)methylene]-D-lysyl-L-leucyl-N6-[bis(ethylamino)methylene]-L-lysyl-L-prolyl-D-alaninamideD-AlaninaMide,N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N6-[bis(ethylaMino)Methylene]-D-lysyl-L-leucyl-N6-[bis(ethylaMino)Methylene]-L-lysyl-L-prolyl-

물성

구조 계산 물성보충 중

XLogP
5.4
극성 표면적
451 Ų
수소 결합 공여자 수
16
수소 결합 수용자 수
16
회전 가능 결합 수
48
무거운 원자 수
112
형식 전하
0
복잡도
3,030

실험 및 물리화학적 성질

Human Drugs · 2건

EMA approved medicines: Human medicine

EMA approved medicines: Human medicine

물리화학적 성질

밀도
1.31 · 1.31±0.1 g/cm3(Predicted)
용해도
DMSO(약간 용해됨), 메탄올(약간 용해됨), 물(약간 용해됨)
산도 계수 (pKa)
9.82 · 9.82±0.15(Predicted)
물리적 상태
고체
색상
흰색에서 황백색까지
안정성
흡습성

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]

P203, P260, P264, P270, P280, P318, P319, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 53 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesRepr. 1B (100%)

안전 데이터

신호 어
Danger
유해·위험 문구
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드 H360

화학 및 산업

약리 정보

ATC Code · 2건

H - Systemic hormonal preparations, excl. sex hormones and insulins

QH - Systemic hormonal preparations, excl. sex hormones and insulin

Protein Binding_In vitro_ protein binding to human plasma is 81.9%.
Pharmacodynamics · 1건

Ganirelix modulates the hypothalamic-pituitary-gonadal axis by causing a rapid, profound, reversible suppression of endogenous gonadotropins. During controlled ovarian stimulation, it suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary gland. Unlike GnRH agonists that causes an initial increase in gonadotropin levels, ganirelix does not cause this effect before premature LH surge inhibition. Ganirelix is also not associated with hypo‐estrogenic side effects, flare‐up, and a long down‐regulation period induced by GnRH agonists. In patients undergoing controlled ovarian stimulation, the median duration of ganirelix treatment was five days. In one study, multiple-dose administration of 0.25 mg ganirelix decreased serum LH, FSH and estradiol (E2) concentrations from baseline by 74, 32, and 25% after the last dose, respectively. Serum hormone levels returned to pre-treatment levels within two days after the last injection.

Mechanism of Action · 1건

Gonadotropin-releasing hormone (GnRH) is a hypothalamus-derived releasing hormone responsible for the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. At midcycle, a large increase in GnRH release results in an LH surge, which leads to several physiologic actions such as ovulation, resumption of meiosis in the oocyte, and luteinization. Luteinization results in a rise in serum progesterone with an accompanying decrease in estradiol levels. Controlled ovarian hyperstimulation (COH) is performed in conjunction with other interventions like in vitro fertilization (IVF) during assisted reproductive technology (ART). COH is beneficial as it allows the scheduling of IVF treatments. During this intervention, inhibiting premature surges of LH is important because premature elevated LH levels can hinder effective multiple follicular maturation and can lead to an undesirable increase in progesterone levels. Ganirelix aims to suppress premature LH surges by competitively blocking the GnRH receptors on the pituitary gonadotroph and subsequent transduction pathways. Ganirelix-induced suppression of gonadotropin secretion is rapid and reversible. The suppression of pituitary LH secretion by ganirelix is more pronounced than that of FSH. An initial release of endogenous gonadotropins has not been detected with ganirelix, which is consistent with an antagonist effect.

관련 반응

0건
반응 기록 만들기
아직 관련 반응이 없습니다

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
(2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]amino]-4-methylpentanoyl]amino]-6-[bis(ethylamino)methylideneamino]hexanoyl]-N-[(2R)-1-amino-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
N-Ac-(2-naphthyl)Ala-2-(4-Cl-Phe)-3-(3-pyridinyl-Ala)-6,8-Et2-hArg-10-AlaNH2-LHRHLHRH, N-acetyl-2-naphthylalanyl(1)-(4-chlorophenylalanyl)(2)-3-pyrdinylalanyl(3)-diethylhomoarginyl(6,8)-alaninamide(10)-(2S)-1-((2S)-2-(((2S)-2-(((2R)-2-(((2S)-2-(((2S)-2-(((2R)-2-(((2R)-2-(((2R)-2-acetamido-3-naphthalen-2-ylpropanoyl)amino)-3-(4-chlorophenyl)propanoyl)amino)-3-pyridin-3-ylpropanoyl)amino)-3-hydroxypropanoyl)amino)-3-(4-hydroxyphenyl)propanoyl)amino)-6-(bis(ethylamino)methylideneamino)hexanoyl)amino)-4-methylpentanoyl)amino)-6-(bis(ethylamino)methylideneamino)hexanoyl)-N-((2R)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide123246-29-7AntagonCHEMBL1251Ganirelix (INN)CID 16134406

데이터베이스 식별자

CAS
124904-93-4
PubChem CID
16130957
DTXSID
DTXSID401027283
ChEMBL
CHEMBL1251
ChEBI
CHEBI:135910
UNII
IX503L9WN0
EC Number
689-234-8
Nikkaji
J419.572H
Biological Half-LifeThe elimination half-life (t½) following subcutaneous administration of a single 250-mcg dose is approximately 13 hours.
Metabolism/MetabolitesThe metabolites are small peptide fragments formed by enzymatic hydrolysis of ganirelix at restricted sites. The 1–4 peptide and 1–6 peptide of ganirelix are the primary metabolites observed in the feces.
FDA Pharmacological Classification · 6건

IX503L9WN0

GANIRELIX

Physiologic Effects [PE] - Decreased GnRH Secretion

Established Pharmacologic Class [EPC] - Gonadotropin Releasing Hormone Receptor Antagonist

Mechanisms of Action [MoA] - Gonadotropin Releasing Hormone Receptor Antagonists

Ganirelix is a Gonadotropin Releasing Hormone Receptor Antagonist. The mechanism of action of ganirelix is as a Gonadotropin Releasing Hormone Receptor Antagonist. The physiologic effect of ganirelix is by means of Decreased GnRH Secretion.

MeSH Pharmacological ClassificationChemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites.
Absorption, Distribution and Excretion · 4건

Ganirelix is rapidly absorbed following subcutaneous administration with a mean absolute bioavailability of approximately 91%. It has a Tmax ranging from one to two hours. Ganirelix reaches steady-state serum concentrations after three days of administration.

Following single-dose intravenous administration of radiolabeled ganirelix to healthy female volunteers, Ganirelix is the major compound present in the plasma (50–70% of total radioactivity in the plasma) up to 4 hours and urine (17.1–18.4% of administered dose) up to 24 hours. Ganirelix is not found in the feces. On average, 97.2% of the total radiolabeled ganirelix dose is recovered in the feces and urine (75.1% and 22.1%, respectively) over 288 h following intravenous single dose administration of 1 mg [<sup>14</sup>C]-ganirelix. Urinary excretion is virtually complete in 24 h, whereas fecal excretion starts to plateau 192 h after dosing.

The mean (SD) volume of distribution of ganirelix in healthy females following subcutaneous administration of a single 250-mcg dose is 43.7 (11.4) L.

Clearance following subcutaneous administration of a single 250-mcg dose is approximately 2.4 L/h.

응용 분야

용도Decapeptide LH-RH antagonist. Ganirelix is used in treatment of infertility.

상·하류 제품 정보

상류 원료

무수초산1,3-디이소프로필 카보디아미드트리플루오로아세트 산1-하이드록시벤조트리아졸 일수화물